Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Share-based Compensation (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Share-based Compensation for 15 consecutive years, with $58.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 11.75% year-over-year to $58.6 million, compared with a TTM value of $217.9 million through Dec 2025, up 11.46%, and an annual FY2025 reading of $217.9 million, up 11.46% over the prior year.
  • Share-based Compensation was $58.6 million for Q4 2025 at Neurocrine Biosciences, up from $53.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $68.5 million in Q2 2023 and bottomed at $32.9 million in Q1 2021.
  • Average Share-based Compensation over 4 years is $49.3 million, with a median of $47.8 million recorded in 2023.
  • Peak annual rise in Share-based Compensation hit 74.28% in 2024, while the deepest fall reached 37.08% in 2024.
  • Year by year, Share-based Compensation stood at $32.9 million in 2021, then rose by 15.81% to $38.1 million in 2023, then surged by 74.28% to $66.4 million in 2024, then dropped by 11.75% to $58.6 million in 2025.
  • Business Quant data shows Share-based Compensation for NBIX at $58.6 million in Q4 2025, $53.7 million in Q3 2025, and $52.8 million in Q2 2025.